CARB-X funding round #1, SDRI 2017, & Antibiotic-tainted seafood

Dear All: Just in case you missed the 30 March annoucement, see at right a snapshot of the first 11 Powered by CARB-X funded companies. Initial funding is $24m, with  potentially a further $24m if the companies hit their milestones. With the funds provided by the companies themselves, the total potential investment is $75m.
 
This is just the start: CARB-X has funds sufficient to do this about another 10 times. Further funding decisions will be announced later this year … it will be a steady drumbeat of funding as we go forward.

​ 
This group of eleven initial companies is remarkably diverse. One company has a very rapid bedside diagnostic. The other 10 encompass 3 potential new classes of small molecule antibiotics, 4 non-traditional products, and 7 new bacterial targets. The projects range from very early to Phase 1.

In parallel, I am now attending the SDRI (Solutions for Drug-Resistant Infection) meeting in Brisbane. Dame Sally Davies has just opened the meeting with an outstanding summary both of the challenge and of the level of international focus. This has been followed by a frankly terrifying talk by Jason Gale (Bloomberg News) in which he reviews his Dec 2016 story entitled How Antibiotic-Tainted Seafood From China Ends Up on Your Table.

I can’t say it enough times … all of you who are working on new therapies (especially those for Gram-negative bacteria) need to get really, really, REALLY busy.

Best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx

Share

NIAID BAA – Biodefense focus / Fireside Chat on diagnostics and more

Dear All, We are swimming in Broad Agency Announcements aka BAAs! As a refresher, I recently shared a BAA from the CDC and one from BARDA — now we have another one from NIAID! There’s a strong biodefense angle here with lots of scope. Key details of each opportunity are as follows and I highly recommend you check

LPAD/Limited Use insights; NI margins for TB and candidiasis

Dear All,  I want to call your attention to next week’s AMDAC (Antimicrobial Drugs Advisory Committee) for rezafungin. This meeting is Tue 24 Jan 2023, 9a-4.30p ET and the meeting materials are provided here.  Rezafungin is an antifungal but please don’t let that dissuade you from attending: this AMDAC promises to be an important discussion

Notable webinars: Pediatric drug development; Drug delivery systems

Dear All, The high-value webinars below have just crossed my radar.  First up, we have a very important 2-part webinar on pediatric antibacterial drug development entitled “Improving the Investigation of New Antibacterial Agents for Use in Children: Ensuring That Our Youngest Patients Also Benefit from Innovative Treatments of Infections Caused by Multi-Drug Resistant Bacteria.” Here are the

CDC BAA: Surveillance, endpoints for decolonization, and more…

Dear All, Greetings in the new year! I just tonight picked up on this fascinating BAA (Broad Agency Announcement) from CDC: BAA 75D301-23-R-72545 as described on this general overview webpage: https://sam.gov/opp/15229982f7c348f69fd35e9a0add8aba/view The BAA itself  Timeline: Initial white papers (max 4 pages, see page 76 of the BAA for details) are due by 3 Feb 2023; Invitations for

Scroll to Top